论文部分内容阅读
目的观察阿德福韦酯联合丹参片治疗乙型肝炎肝纤维化的临床价值。方法选取医院收治的慢性乙肝患者120例为研究对象,随机分为观察组和对照组,每组60例。2组均给予常规治疗,对照组使用阿德福韦酯片治疗,观察组在对照组基础上联合丹参片治疗。观察2组治疗前后病毒学指标、肝纤维化指标[Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)、层黏蛋白(LN)、血清透明质酸(HA)]及肝功能[天冬氨酸氨基转氨酶(AST)、谷氨酸氨基转氨酶(ALT)]变化情况。结果 2组患者治疗前后病毒学指标无显著差异(P>0.05)。治疗后,观察组ALT、AST数值低于对照组(P<0.01);观察组Ⅳ-C、PCⅢ、LN、HA数值均低于对照组(P<0.01)。结论对于慢性乙肝者,使用阿德福韦酯联合丹参片加以治疗,效果优于单一给药,可缓解肝纤维化进展,控制/消退肝脏内炎性活动,改善患者肝脏功能,值得进一步推广。
Objective To observe the clinical value of adefovir dipivoxil combined with danshen tablet in treating hepatitis B liver fibrosis. Methods A total of 120 chronic hepatitis B patients admitted to hospital were selected as study subjects and randomly divided into observation group and control group with 60 cases in each group. Both groups were given routine treatment, the control group treated with adefovir dipivoxil, the observation group on the basis of the control group combined with Salvia tablets. The changes of viral markers, hepatic fibrosis indexes (Ⅳ-C, PC Ⅲ, laminin, serum hyaluronic acid) and liver function in the two groups were observed before and after treatment. Aspartate aminotransferase (AST), glutamate aminotransferase (ALT)] changes. Results There was no significant difference in virological parameters between the two groups before and after treatment (P> 0.05). After treatment, the ALT and AST values in the observation group were lower than those in the control group (P <0.01). The values of Ⅳ-C, PCⅢ, LN and HA in the observation group were lower than those in the control group (P <0.01). Conclusions In patients with chronic hepatitis B, treatment with adefovir dipivoxil combined with Danshen tablets is superior to single administration, which can relieve the progression of liver fibrosis, control / extinction of inflammatory activity in the liver, and improve liver function of patients, which deserves further promotion.